financetom
Business
financetom
/
Business
/
Sealed Air Shines In Q2 On Strength In Food Business, Shares Move Higher
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sealed Air Shines In Q2 On Strength In Food Business, Shares Move Higher
Aug 8, 2024 10:09 AM

Sealed Air Corporation ( SEE ) shares are trading higher after the company reported second quarter results.

The company reported adjusted earnings per share of 83 cents, beating the street view of 64 cents. The company reported quarterly revenues of $1.345 billion, beating the analyst consensus of $1.307 billion.

Revenues decreased 3% as reported, with EMEA decreasing 5%, APAC decreasing 3% and the Americas decreasing 2%.

Net sales decreased $24 million, or 2%, on a constant dollar basis.

The current year results were impacted by $27 million of Special Items expense, including $9 million of restructuring and other associated costs related to the cost take-out to grow program.

Also Read: Asia Mixed, Europe Markets Dip; Crude Falls Below $75 And Dollar Slips – Global Markets Today While US Slept

Adjusted EBITDA was $285 million, or 21.2% of net sales, as compared to $280 million, or 20.3% in the prior year.

The increase in Adjusted EBITDA was primarily due to lower operating costs driven by productivity benefits and higher volumes, partially offset by unfavorable net price realization.

“Our second quarter results were ahead of our expectations, reflecting strong sequential demand within our Food business, accelerated benefits from our CTO2Grow program that more than offset the continued pressure within our Protective business,” said Patrick Kivits, Sealed Air’s CEO. 

Total debt was $4.6 billion as of June 30, with approximately $1.4 billion of available liquidity.

Outlook: The company sees FY24 revenues of $5.2 billion to $5.6 billion versus the $5.4 billion estimate (prior view: $5.2 billion to $5.6 billion). It expects an adjusted EPS of $2.65 to $3.05 versus an estimate of $2.88.

SEE Price Action: Sealed Air ( SEE ) shares are trading higher by 6.11% to $36.49 at last check Thursday.

Read Next:

Global Market Crash Sparks Reflection On Jeff Bezos’ 2000 Dotcom Comments After Amazon’s 80% Plunge: ‘We’re A Company That Wants To Be Weighed, And Over Time We Will Be’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blake Lively seeks to end Justin Baldoni's 'vengeful' $400 million defamation lawsuit
Blake Lively seeks to end Justin Baldoni's 'vengeful' $400 million defamation lawsuit
Mar 20, 2025
* Lively says Baldoni 'weaponizing' defamation case * 'It Ends With Us' co-stars allege competing smear campaigns * Baldoni's lawyers not immediately available for comment (Recasts first paragraph; adds details from Lively court filing, lawyers' comments, paragraphs 2-3, 11-15) By Jonathan Stempel NEW YORK, March 20 (Reuters) - Actress Blake Lively asked a U.S. judge on Thursday to dismiss actor...
--Street Color: Lyft to Roll Out Driverless Rides This Summer
--Street Color: Lyft to Roll Out Driverless Rides This Summer
Mar 20, 2025
02:32 PM EDT, 03/20/2025 (MT Newswires) -- Price: 11.72, Change: -0.01, Percent Change: -0.04 ...
Mariah Carey wins copyright lawsuit over 'All I Want for Christmas Is You'
Mariah Carey wins copyright lawsuit over 'All I Want for Christmas Is You'
Mar 20, 2025
* Judge rules songs not objectively similar for copyright case * Carey's song tops Billboard Hot 100 every holiday season since 2019 * Songwriters ordered to pay part of Carey's legal fees By Blake Brittain March 20 (Reuters) - Pop singer Mariah Carey defeated a lawsuit claiming she illegally copied elements of her holiday megahit All I Want for Christmas...
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Mar 20, 2025
Monte Rosa Therapeutics Inc ( GLUE ). on Thursday revealed clinical results from its MRT-6160 Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study. The study objectives were to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics, including VAV1 degradation and its impact on T and B cell function following ex vivo stimulation. Results demonstrated sustained, dose-dependent VAV1 degradation of greater than...
Copyright 2023-2026 - www.financetom.com All Rights Reserved